- Home
- XOMAP vs VLY Comparison
XOMAP vs VLY Comparison
Compare XOMAP & VLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- VLY
- Stock Information
- Founded
- XOMAP N/A
- VLY 1927
- Country
- XOMAP United States
- VLY United States
- Employees
- XOMAP 13
- VLY N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- VLY Major Banks
- Sector
- XOMAP Health Care
- VLY Finance
- Exchange
- XOMAP Nasdaq
- VLY Nasdaq
- Market Cap
- XOMAP N/A
- VLY N/A
- IPO Year
- XOMAP N/A
- VLY N/A
- Fundamental
- Price
- XOMAP $25.62
- VLY $9.60
- Analyst Decision
- XOMAP
- VLY Buy
- Analyst Count
- XOMAP 0
- VLY 13
- Target Price
- XOMAP N/A
- VLY $10.31
- AVG Volume (30 Days)
- XOMAP N/A
- VLY 8.6M
- Earning Date
- XOMAP N/A
- VLY 01-23-2025
- Dividend Yield
- XOMAP N/A
- VLY 4.62%
- EPS Growth
- XOMAP N/A
- VLY N/A
- EPS
- XOMAP N/A
- VLY 0.69
- Revenue
- XOMAP N/A
- VLY $1,518,099,000.00
- Revenue This Year
- XOMAP N/A
- VLY N/A
- Revenue Next Year
- XOMAP N/A
- VLY $8.52
- P/E Ratio
- XOMAP N/A
- VLY $13.82
- Revenue Growth
- XOMAP N/A
- VLY N/A
- 52 Week Low
- XOMAP N/A
- VLY $6.47
- 52 Week High
- XOMAP N/A
- VLY $11.10
- Technical
- Relative Strength Index (RSI)
- XOMAP 47.68
- VLY 47.96
- Support Level
- XOMAP $25.57
- VLY $9.76
- Resistance Level
- XOMAP $25.83
- VLY $10.13
- Average True Range (ATR)
- XOMAP 0.11
- VLY 0.24
- MACD
- XOMAP -0.01
- VLY -0.06
- Stochastic Oscillator
- XOMAP 24.24
- VLY 17.61
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.